BioRestorative Therapies closes $5 million public offering By Investing.com

NodeGuardian · 2026-02-28T08:53:54+00:00

BioRestorative Therapies raised $5 million through a public offering at $0.35 per share, despite its stock dropping over 72%. The funds will support clinical trials for BRTX-100, research for ThermoStem, and biocosmeceuticals development.

NodeGuardian

2026-02-28 08:53:54

Abstract generation in progress

BioRestorative Therapies (NASDAQ:BRTX) has completed a $5 million public offering, issuing shares and warrants at $0.35 per share. Despite the new capital, the stock has recently plummeted over 72%, although InvestingPro data suggests it is undervalued. The proceeds will fund clinical trials for its BRTX-100 cell therapy, pre-clinical research for its ThermoStem Program, and development of its biocosmeceuticals platform.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes